Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Test type
1.1.2. Technology
1.1.3. End use
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Test type outlook
2.2.2. Technology outlook
2.2.3. End use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Heart Failure POC & LOC Devices Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Heart Failure POC & LOC Devices Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Heart Failure POC & LOC Devices: Test Type Estimates & Trend Analysis
4.1. Heart Failure POC & LOC Devices Market: Key Takeaways
4.2. Heart Failure POC & LOC Devices Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Proteomic Testing
4.3.1. Proteomic testing market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Metabolomic Testing
4.4.1. Metabolomic testing market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Genomic Testing
4.5.1. Genomic testing market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Heart Failure POC & LOC Devices: Technology Estimates & Trend Analysis
5.1. Heart Failure POC & LOC Devices Market: Key Takeaways
5.2. Heart Failure POC & LOC Devices Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Microfluidics
5.3.1. Microfluidics market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Array-based Systems
5.4.1. Array-based systems market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Others
5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Heart Failure POC & LOC Devices: End Use Estimates & Trend Analysis
6.1. Heart Failure POC & LOC Devices Market: Key Takeaways
6.2. Heart Failure POC & LOC Devices Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Clinics
6.3.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Hospitals
6.4.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Home
6.5.1. Home market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Assisted Living Healthcare Facilities
6.6.1. Assisted living healthcare facilities market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Laboratory
6.7.1. Laboratory market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Heart Failure POC & LOC Devices Market: Regional Estimates & Trend Analysis
7.1. Regional Outlook
7.2. Heart Failure POC & LOC Devices Market by Region: Key Takeaways
7.3. North America
7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.3.2. U.S.
7.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.3.3. Canada
7.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.2. Germany
7.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.3. France
7.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.4. Italy
7.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.5. Spain
7.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.6. Denmark
7.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.7. Sweden
7.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.8. Norway
7.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.2. China
7.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.3. India
7.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.4. Australia
7.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.5. Thailand
7.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.6. South Korea
7.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6.2. Mexico
7.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6.3. Argentina
7.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.3. UAE
7.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.4. Kuwait
7.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Market Participant Categorization
8.2.1. Abbott Laboratories
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Siemens Healthineers
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Product benchmarking
8.2.2.4. Strategic initiatives
8.2.3. Danaher
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Instrumentation Laboratory
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. F. Hoffmann-La Roche Ltd.
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. bioMérieux S.A.
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Abaxis, Inc.
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Quidel Corporation
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. Jant Pharmacal Corporation
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiative
8.2.10. Trinity Biotech
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Product benchmarking
8.2.10.4. Strategic initiatives
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer